Sword Bio Appoints Matthew Langevin as Chief Operating Officer
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs from development to clinical trials, announces the appointment of Matthew Langevin as Chief Operating Officer.
Matt joins Sword with exceptional experience and a proven track record in the contract research space. Most notably, he was Co-Founder of BioAgilytix, which he led through extraordinary growth. Matt set the culture at BioAgilytix by prioritizing science and clients above all. He has over 25 years of leadership experience involving assay troubleshooting, development, qualification, validation, and sample analysis in non-regulated and GLP environments.
“I’m thrilled to have Matt join our team and lead our operations,” said David Dingott, CEO. “Matt’s experience in co-founding and building BioAgilytix gives him the unique ability to scale Sword Bio with the principles that matter to us most: leading with science, the highest levels of customer transparency, and the utmost integrity. Matt has another key goal: to begin customer projects quickly for small and medium sized clients in addition to our large clients. He recognizes the critical need for getting projects underway and completed with the urgency they deserve.”
“I’m excited to join Sword and complete the GLP architecture needed to help support additional valued clients,” said Matt. “It is an exciting time for Sword as we expand our capabilities and team. We have capacity and would love to help you with your bioanalytical needs.”
Sword Bio is a bioanalytical CRO satisfying the needs of biotech and pharmaceutical companies. The sword team is built with experts in assay development, validation and sample analysis under RUO, Spirit of GLP and GLP (Q3 2023). We support our clients with PK, biomarker, and immunogenicity assays for research, pre-clinical and clinical studies.
Sword’s team of highly experienced science and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. We pride ourselves on starting projects quickly so that our clients can quickly achieve their goals. For more information, visit www.swordbio.com.